NEPHROSCAN

DistributionTechnetium Tc 99m succimer is distributed in the plasma, bound to plasma proteins following intravenous administration. In humans, 53% to 70% of the intravenously administered technetium Tc 99m is protein bound. There is negligible activity in the red blood cells. At 6 hours about 20% of the dose is concentrated in each kidney.

EliminationApproximately 16% of the technetium Tc 99m succimer activity is excreted in the urine within 2 hours.

The following clinically significant adverse reactions are discussed elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] The following adverse reactions associated with the use of NEPHROSCAN were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposu...

None None ( 4 )

Hypersensitivity Reactions: Have appropriate instruments and medications necessary for immediate treatment of allergic reactions and monitor patients for hypersensitivity reactions during and after administration ( 5.1 ) Radiation risks: Ensure safe handling to minimize radiation exposure to patients and health care workers ( 5.2 ) Risk in Patients with Advanced Renal Failure: Image interpretation may be affected as the kidneys may not absorb technetium Tc 99m succimer. ( 5.3 ) 5.1 Hypersensitiv...